Chandra Deepak, Ramana Kota V, Friedrich Brian, Srivastava Sanjay, Bhatnagar Aruni, Srivastava Satish K
Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, TX 77555, USA.
Chem Biol Interact. 2003 Feb 1;143-144:605-12. doi: 10.1016/s0009-2797(02)00191-6.
Apoptosis of vascular endothelial cells (VECs) and concomitant proliferation of the underlying vascular smooth muscle cells (VSMCs) in large arteries are the key features of atherosclerosis and restenosis. However, the mechanisms underlying endothelial cell death and abnormal smooth muscle cell proliferation during the development of vascular lesions remain unclear. We have previously demonstrated that treatment with inhibitors of the aldehyde-metabolizing enzyme and aldose reductase (AR) attenuates restenosis of balloon-injured rat carotid arteries. The inhibition of AR also prevents the apoptosis of VECs induced by the tumor necrosis factor-alpha (TNF-alpha). Apoptosis of the VECs was determined by the incorporation of [3H]-thymidine and the activation of caspase-3. Stimulation of the VECs with TNF-alpha led to an increase in the DNA-binding activity of the transcription factor, nuclear factor-kappa binding protein (NF-kappaB) and the induction of the adhesion molecule (ICAM)-1. Treatment of VECs with the AR inhibitor, tolrestat, prevented the activation of NF-kappaB and diminished ICAM-1 induction stimulated by TNF-alpha. These results indicate an obligatory requirement of AR activity in the transduction of intracellular signaling initiated by the ligation of the TNF-alpha receptors leading to the activation of NF-kappaB. Although the specific signaling events interrupted by AR inhibition remain unknown, our results suggest that product(s) of AR catalysis may be essential for NF-kappaB activation. These observations could form the basis of future investigations into the therapeutic utility of AR inhibitors in preserving endothelial function and integrity during atherosclerosis and diabetes.
大动脉中血管内皮细胞(VECs)凋亡以及其下的血管平滑肌细胞(VSMCs)伴随增殖是动脉粥样硬化和再狭窄的关键特征。然而,血管病变发展过程中内皮细胞死亡和异常平滑肌细胞增殖的潜在机制仍不清楚。我们之前已证明,用醛代谢酶和醛糖还原酶(AR)抑制剂治疗可减轻球囊损伤大鼠颈动脉的再狭窄。抑制AR还可防止肿瘤坏死因子-α(TNF-α)诱导的VECs凋亡。通过掺入[3H] - 胸苷和激活caspase-3来确定VECs的凋亡。用TNF-α刺激VECs会导致转录因子核因子-κB结合蛋白(NF-κB)的DNA结合活性增加以及诱导黏附分子(ICAM)-1。用AR抑制剂托瑞司他处理VECs可防止NF-κB的激活,并减少TNF-α刺激诱导的ICAM-1。这些结果表明,AR活性在由TNF-α受体结合引发的细胞内信号转导中是必需的,该信号转导导致NF-κB的激活。尽管AR抑制所中断的具体信号事件仍不清楚,但我们的结果表明AR催化产物可能对NF-κB激活至关重要。这些观察结果可为未来研究AR抑制剂在动脉粥样硬化和糖尿病期间维持内皮功能和完整性的治疗效用奠定基础。